Outcomes of application Calumid in the second line of treatment local and advanced prostate cancer
Bicalutamide is applied in the second line of hormonal therapy. The drug has a high antiandrogen activity. We observed 12 patients with locally advanced (9) and disseminated (3) prostate cancer. The median of progression on a background of hormone therapy as the first line of treatment locally advanced prostate cancer was 38 months, and metastatic cancer - 20 months ^=0,801)^^(1^ 150 mg per day was prescribed as the second line of treatment. The survival median on a background of the second line of hormone therapy with Calumid application for the patients with locally advanced prostate cancer was 8 months, and metastatic prostate cancer 12 months (р=0,248). Calumid 150 mg daily application did not cause complications or not portable side effects